Published in N Engl J Med on May 19, 2011
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med (2011) 2.98
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis (2014) 2.14
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis (2012) 1.97
Complex population dynamics and the coalescent under neutrality. Genetics (2011) 1.81
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
Viral phylodynamics. PLoS Comput Biol (2013) 1.71
HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med (2013) 1.55
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
HIV transmission. Cold Spring Harb Perspect Med (2012) 1.52
Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science (2014) 1.46
Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis (2013) 1.43
Understanding the HIV disparities between black and white men who have sex with men in the USA using the HIV care continuum: a modeling study. Lancet HIV (2014) 1.37
Has testing been normalized? An analysis of changes in barriers to HIV testing among men who have sex with men between 2000 and 2010 in Scotland, UK. HIV Med (2012) 1.34
The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol (2013) 1.34
Iron metabolism and the innate immune response to infection. Microbes Infect (2011) 1.32
Measuring population transmission risk for HIV: an alternative metric of exposure risk in men who have sex with men (MSM) in the US. PLoS One (2012) 1.28
Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS (2012) 1.26
Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol (2013) 1.26
A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology (2013) 1.24
Perceived acceptability of home-based couples voluntary HIV counseling and testing in Northern Tanzania. AIDS Care (2011) 1.23
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23
Socially-integrated transdisciplinary HIV prevention. AIDS Behav (2014) 1.18
How can we better identify early HIV infections? Curr Opin HIV AIDS (2015) 1.18
Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa. AIDS (2015) 1.16
The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS (2011) 1.14
Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence. Proc Natl Acad Sci U S A (2014) 1.13
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa. AIDS (2013) 1.13
Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts. PLoS Med (2015) 1.12
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Trends in the spectrum of engagement in HIV care and subsequent clinical outcomes among men who have sex with men (MSM) at a Boston community health center. AIDS Patient Care STDS (2013) 1.09
Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology (2014) 1.09
Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PLoS One (2013) 1.04
The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect (2011) 1.01
Episodic HIV Risk Behavior Can Greatly Amplify HIV Prevalence and the Fraction of Transmissions from Acute HIV Infection. Stat Commun Infect Dis (2012) 1.00
Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One (2012) 1.00
Should we treat acute HIV infection? Curr HIV/AIDS Rep (2012) 1.00
Macrophage polarization: convergence point targeted by mycobacterium tuberculosis and HIV. Front Immunol (2011) 0.99
Population genomics of intrapatient HIV-1 evolution. Elife (2015) 0.99
The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr (2013) 0.98
Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population. PLoS One (2014) 0.98
Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS (2013) 0.98
Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol (2012) 0.97
Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. AIDS Res Hum Retroviruses (2014) 0.96
HIV testing and linkage to services for youth. J Int AIDS Soc (2015) 0.96
Changes in Natural Killer cell activation and function during primary HIV-1 Infection. PLoS One (2013) 0.96
Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr (2013) 0.95
Mediators of antiretroviral adherence: a multisite international study. AIDS Care (2012) 0.94
Evaluation of an empiric risk screening score to identify acute and early HIV-1 infection among MSM in Coastal Kenya. AIDS (2013) 0.94
Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med (2016) 0.93
Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing. PLoS One (2013) 0.92
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One (2013) 0.92
Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis (2013) 0.92
Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. Proc Natl Acad Sci U S A (2014) 0.91
Assessing willingness to test for HIV among men who have sex with men using conjoint analysis, evidence for uptake of the FDA-approved at-home HIV test. AIDS Care (2013) 0.91
The HIV Epidemic: High-Income Countries. Cold Spring Harb Perspect Med (2012) 0.90
Performance of an alternative HIV diagnostic algorithm using the ARCHITECT HIV Ag/Ab Combo assay and potential utility of sample-to-cutoff ratio to discriminate primary from established infection. J Clin Virol (2013) 0.90
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. J Virus Erad (2015) 0.88
Screening for acute HIV infection in community-based settings: Cost-effectiveness and impact on transmissions. J Infect (2016) 0.87
Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens. J Int AIDS Soc (2015) 0.87
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. AIDS Res Hum Retroviruses (2015) 0.87
Targeting screening and social marketing to increase detection of acute HIV infection in men who have sex with men in Vancouver, British Columbia. AIDS (2013) 0.87
Using a Mobile Health Intervention to Support HIV Treatment Adherence and Retention Among Patients at Risk for Disengaging with Care. AIDS Patient Care STDS (2016) 0.87
Rectal microbicide development. Curr Opin HIV AIDS (2012) 0.86
HIV sexual transmission is predominantly driven by single individuals rather than discordant couples: a model-based approach. PLoS One (2013) 0.86
Diagnosing acute and prevalent HIV-1 infection in young African adults seeking care for fever: a systematic review and audit of current practice. Int Health (2014) 0.86
Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (2014) 0.86
Future of phylogeny in HIV prevention. J Acquir Immune Defic Syndr (2013) 0.85
HIV-1 concentrations in human breast milk before and after weaning. Sci Transl Med (2013) 0.84
Computational inference methods for selective sweeps arising in acute HIV infection. Genetics (2013) 0.84
An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load. PLoS Comput Biol (2014) 0.84
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California. Ann Epidemiol (2014) 0.84
Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources. PLoS One (2016) 0.83
Prevalence of undiagnosed acute and chronic HIV in a lower-prevalence urban emergency department. Am J Public Health (2014) 0.83
Short communication: Investigation of incident HIV infections among U.S. army soldiers deployed to Afghanistan and Iraq, 2001-2007. AIDS Res Hum Retroviruses (2012) 0.83
Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods (2013) 0.83
Gut Microbiota in HIV Infection: Implication for Disease Progression and Management. Gastroenterol Res Pract (2014) 0.83
Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel Nuclease-Linked Fluorescence Oligonucleotide Assay. PLoS One (2015) 0.83
Dynamic Variation in Sexual Contact Rates in a Cohort of HIV-Negative Gay Men. Am J Epidemiol (2015) 0.82
High-density lipoprotein-mediated cholesterol efflux capacity is improved by treatment with antiretroviral therapy in acute human immunodeficiency virus infection. Open Forum Infect Dis (2014) 0.82
HIV delays IFN-α production from human plasmacytoid dendritic cells and is associated with SYK phosphorylation. PLoS One (2012) 0.82
Pulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the Literature. Front Pediatr (2015) 0.82
Impact of viral load and the duration of primary infection on HIV transmission: systematic review and meta-analysis. AIDS (2014) 0.82
Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells. Viruses (2012) 0.82
Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev (2017) 0.82
Impact of early-stage HIV transmission on treatment as prevention. Proc Natl Acad Sci U S A (2014) 0.81
Targeting the use of pooled HIV RNA screening to reduce cost in health department STD clinics: New York City, 2009-2011. Public Health Rep (2015) 0.81
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
The challenge of finding a cure for HIV infection. Science (2009) 8.41
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity (2007) 6.36
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 5.05
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr (1994) 4.81
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Rethinking prevention of HIV type 1 infection. Clin Infect Dis (2010) 4.19
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Reduction of HIV concentration during acute infection: independence from a specific immune response. Science (1996) 2.98
How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS (2007) 2.77
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med (1998) 2.50
HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr (2011) 2.49
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 2.27
Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol (2004) 2.24
B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood (2010) 2.05
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS (2008) 2.04
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol (2009) 1.96
The unexpected movement of the HIV epidemic in the Southeastern United States: transmission among college students. J Acquir Immune Defic Syndr (2005) 1.93
Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.89
HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS (2004) 1.89
Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS (2004) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav (2007) 1.76
Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med (2007) 1.76
Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis (2010) 1.71
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol (2008) 1.69
The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS (2008) 1.54
Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46
Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav (2011) 1.41
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
State of the art for diagnosis of HIV infection. Clin Infect Dis (2007) 1.34
The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math Biosci (1998) 1.32
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Male circumcision for HIV prevention: current research and programmatic issues. AIDS (2010) 1.24
Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS (2008) 1.22
Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis (2008) 1.18
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol (2010) 1.16
Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog (2010) 1.16
A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. J Infect Dis (2010) 1.15
Amplified HIV transmission during early-stage infection. J Infect Dis (2006) 1.12
Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS (2010) 1.11
Implications of increased infectivity in early-stage HIV infection. Application of a Bernoulli-process model of HIV transmission. Eval Rev (1996) 1.07
Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS (2008) 1.04
Innate immune responses in primary HIV-1 infection. Curr Opin HIV AIDS (2008) 1.02
Performance evaluation of the new fully automated human immunodeficiency virus antigen-antibody combination assay designed for blood screening. Transfusion (2008) 0.97
Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res Ther (2006) 0.96
A controlled study of the effectiveness of public health HIV partner notification services. AIDS (2009) 0.96
HIV's vagina travelogue. Immunity (2007) 0.90
Modelling the natural history of HIV infection in individuals and its epidemiological implications. Bull Math Biol (2001) 0.86
Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis. Curr Infect Dis Rep (2008) 0.83
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 4.74
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest (2008) 4.30
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19
A structural basis for immunodominant human T cell receptor recognition. Nat Immunol (2003) 3.15
Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis (2002) 2.98
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature (2009) 2.78
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol (2002) 2.64
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Simian immunodeficiency virus infection of chimpanzees. J Virol (2005) 2.46
SIVcpz in wild chimpanzees. Science (2002) 2.45
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol (2006) 2.41
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34